Latest Galena Biopharma (GALE) Headlines
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Galena Biopharma, Inc. and Certain Officers -- GALE
GlobeNewswire - 2 hrs 25 mins ago
Pomerantz LLP has filed a class action lawsuit against Galena Biopharma, Inc. ("Galena" or the "Company") (Nasdaq:GALE) and certain of its officers. The class action, filed in United States District Court, District of Oregon, and docketed under 3:14-cv-00410-HZ, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Galena securities between March 12, 2013 and February 11, 2014, both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Attention Galena Biopharma, Inc. Investors: Galena Misled Investors According to a Recently Filed Class Action
PR Newswire - Wed Mar 12, 3:27PM CDT
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Galena Biopharma, Inc. (NASDAQ: GALE) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of Oregon. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between November 6, 2013 and February 14, 2014 (the "Class Period"). Galena is a biopharmaceutical company focusing on the development of oncology treatments.
The Law Offices of Marc S. Henzel Announces Class Action Lawsuit against Galena Biopharma, Inc. (Nasdaq: GALE) and Certain Officers -- Galena Biopharma, Inc. (Nasdaq: GALE) was filed on behalf of stockholders.
PR Newswire - Wed Mar 12, 8:05AM CDT
The Law Offices of Marc S. Henzel announces that a class action lawsuit was filed against Galena Biopharma, Inc. (Nasdaq: GALE) ("GALE" or the "Company") and certain of its officers in United States District Court for the District of Oregon on behalf of a class (the "Class") comprising all purchasers of Galena Biopharma, Inc. (Nasdaq: GALE) securities between November 6, 2013 and February 14, 2014, inclusive (the "Class Period").
Wolf Haldenstein Announces Investigation of Galena Biopharma, Inc.
Business Wire - Tue Mar 11, 5:07PM CDT
The law firm of Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating potential federal securities claims against Galena Biopharma, Inc. ("Galena" or the "Company") (NASDAQ:GALE) and certain of its officers and directors in connection with allegations that the Company made materially misleading representations and omissions in connection with a brand awareness campaign aimed at boosting its stock price.
Investor-Edge.com Pre-market Biotech Picks: Rexahn Pharma, Amgen, Galena Biopharma, and MannKind
PR Newswire - Tue Mar 11, 10:32AM CDT
On Monday, March 10, 2014, the NASDAQ Composite ended at 4,334.45, down 0.04%, the Dow Jones Industrial Average fell 0.21% to 16,418.68, and the S&P 500 closed at 1,877.17, down 0.05%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 689.78, up 0.39%, and has gained 4.92% in the last one month. Investor-Edge.com has initiated coverage on the following equities: Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Amgen Inc. (NASDAQ: AMGN), Galena Biopharma Inc. (NASDAQ: GALE), and MannKind Corporation (NASDAQ: MNKD). Free research on these four companies can be accessed at:
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Files Class Action Lawsuit Against Galena Biopharma, Inc.
Business Wire - Tue Mar 11, 9:32AM CDT
Glancy Binkow & Goldberg LLP, representing investors of Galena Biopharma, Inc. ("Galena" or the "Company") (NASDAQ:GALE), has filed a class action lawsuit in the United States District Court for the District of Oregon on behalf of a class (the "Class") comprising all purchasers of Galena securities between November 6, 2013 and February 14, 2014, inclusive (the "Class Period").
Lawsuit on Behalf of Investors in Galena Biopharma Inc (GALE) Announced by Shareholders Foundation
GlobeNewswire - Mon Mar 10, 9:02AM CDT
The Shareholders Foundation, Inc. announces that a lawsuit was filed on behalf of certain purchasers Galena Biopharma Inc (GALE) common stock over alleged violations of Federal Securities Laws by Galena Biopharma Inc in connection with certain allegedly false and misleading statements.
Shareholder Rights Law Firm Johnson & Weaver, LLP Has Filed a Class Action Lawsuit Against Galena Biopharma, Inc. and Certain Officers
Business Wire - Sat Mar 08, 5:01AM CST
Shareholder rights law firm Johnson & Weaver, LLP announced today that it filed a class action lawsuit in the United States District Court for the District of Oregon on behalf of purchasers of Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena") (GALE) common stock during the period between November 6, 2013 and February 14, 2014 (the "Class Period").
EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Against Galena Biopharma, Inc. -- GALE
GlobeNewswire - Fri Mar 07, 10:35PM CST
The Rosen Law Firm, P.A. today announced that a class action lawsuit has been filed on behalf of all purchasers of the common stock of Galena Biopharma, Inc. (Nasdaq:GALE) from November 6, 2013 to February 14, 2014, seeking remedies under the federal securities laws.
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Galena Biopharma, Inc. -- GALE
GlobeNewswire - Fri Mar 07, 6:00PM CST
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the District of Oregon on behalf of all persons who purchased or otherwise acquired the securities of Galena Biopharma, Inc. ("Galena" or the "Company") (Nasdaq:GALE) during the period between November 6, 2013 and February 14, 2014 (the "Class Period").
GALENA BIOPHARMA, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against GALENA BIOPHARMA, INC. and Its Board and a Lead Plaintiff Deadline of May 5, 2014 -- GALE
GlobeNewswire - Fri Mar 07, 2:59AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of holders of Galena Biopharma, Inc. ("Galena" or the "Company") (Nasdaq:GALE) securities between November 6, 2013 and February 14, 2014.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Galena Biopharma, Inc. to Contact Brower Piven Before the May 5, 2014 Lead Plaintiff Deadline -- GALE
GlobeNewswire - Fri Mar 07, 2:59AM CST
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of purchasers of Galena Biopharma, Inc. ("Galena" or the "Company") (Nasdaq:GALE) common stock during the period between November 6, 2013 and February 14, 2014, inclusive (the "Class Period").
Cohen, Placitella & Roth, PC Investigating Galena Biopharma, Inc. for Improper Stock Promotion
PR Newswire - Thu Mar 06, 6:20PM CST
Cohen, Placitella & Roth, PC is investigating claims on behalf of investors who purchased Galena Biopharma, Inc. ("Galena" or "Company") (NASDAQ: GALE) stock between November 6, 2013 and February 14, 2014, inclusive. The investigation concerns whether Galena disseminated materially false and/or misleading information to investors in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Galena Biopharma, Inc.
PR Newswire - Thu Mar 06, 2:02PM CST
Bernstein Liebhard LLP today announced that a class action has been commenced in the United States District Court for the District of Oregon on behalf of purchasers (the "Class") of common stock of Galena Biopharma, Inc. ("Galena" or the "Company") (NASDAQ: GALE) during the period of November 6, 2013 and February 14, 2014 (the "Class Period").
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Galena Biopharma, Inc.
Business Wire - Wed Mar 05, 6:49PM CST
Robbins Geller Rudman & Dowd LLP ("Robbins Geller") (http://www.rgrdlaw.com/cases/galena/) today announced that a class action has been commenced in the United States District Court for the District of Oregon on behalf of purchasers of Galena Biopharma, Inc. ("Galena") (NASDAQ:GALE) common stock during the period between November 6, 2013 and February 14, 2014 (the "Class Period").
Galena Biopharma to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 6:11AM CST
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer will present a corporate update at the 26 Annual ROTH Conference. The presentation will take place on Monday, March 10, 2014 at 9:00 a.m. PT at The Ritz-Carlton Hotel in Dana Point, CA.
Targazyme, Inc. Appoints Dr. Mark W. Schwartz to Board of Directors
Marketwire - Tue Mar 04, 5:01AM CST
Targazyme, Inc. (formerly America Stem Cell, Inc., the "Company") announced today that it has appointed Mark W. Schwartz, Ph.D. to the Company's Board of Directors. Dr. Schwartz will serve the Company as an independent member of the Board. As an independent director, Dr. Schwartz will assist in the Company in further enhancing its corporate governance protocols and oversight committees, as well as assist management in setting and meeting corporate goals, including establishing key strategic partnerships and providing guidance on long-term capital raising in both private and public markets. With the appointment of Dr. Schwartz as the Company's fourth Board member and third independent director, the Company has achieved Sarbanes-Oxley ("SOX") compliance with respect to Board composition.
Galena Biopharma Launches Galena Patient Services (GPS)
GlobeNewswire - Mon Mar 03, 6:05AM CST
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the launch of Galena Patient Services (GPS), a full-service support program designed to enhance patient access to commercial products offered by the Company. Currently, Galena markets Abstral(R) (fentanyl) Sublingual Tablets for the treatment of breakthrough cancer pain.
Galena Biopharma Bolsters NeuVax(TM) (nelipepimut-S) Intellectual Property With Patent Acceptance in Australia
GlobeNewswire - Fri Feb 28, 6:19AM CST
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that it has received a Notice of Acceptance from the Australian Patent Office for a patent covering the use of Galena's development product candidate, NeuVax(TM) (nelipepimut-S), a HER2/neu peptide vaccine, for inducing protective or therapeutic immunity to breast cancer recurrence in patients having low-to-intermediate HER2 IHC ratings of 1+ or 2+ and a FISH rating of less than 2.0 ± 20% for CYP17 to HER2/neu gene expression ratio. The patent provides NeuVax the exclusivity for this indication until 2028, not including any patent term extensions.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of GALENA BIOPHARMA, INC. for Possible Breaches of Fiduciary Duty
PR Newswire - Thu Feb 27, 10:10AM CST
Levi & Korsinsky is investigating Galena Biopharma, Inc. ("Galena Biopharma" or the "Company") (Nasdaq: GALE) for possible breaches of fiduciary duty. The investigation concerns whether a series of statements Galena Biopharma made regarding its business, prospects, and operations were materially false and misleading.
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Galena Biopharma, Inc. and Certain Officers -- GALE
GlobeNewswire - 2 hrs 25 mins ago
Pomerantz LLP has filed a class action lawsuit against Galena Biopharma, Inc. ("Galena" or the "Company") (Nasdaq:GALE) and certain of its officers. The class action, filed in United States District Court, District of Oregon, and docketed under 3:14-cv-00410-HZ, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Galena securities between March 12, 2013 and February 11, 2014, both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Attention Galena Biopharma, Inc. Investors: Galena Misled Investors According to a Recently Filed Class Action
PR Newswire - Wed Mar 12, 3:27PM CDT
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Galena Biopharma, Inc. (NASDAQ: GALE) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of Oregon. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between November 6, 2013 and February 14, 2014 (the "Class Period"). Galena is a biopharmaceutical company focusing on the development of oncology treatments.
The Law Offices of Marc S. Henzel Announces Class Action Lawsuit against Galena Biopharma, Inc. (Nasdaq: GALE) and Certain Officers -- Galena Biopharma, Inc. (Nasdaq: GALE) was filed on behalf of stockholders.
PR Newswire - Wed Mar 12, 8:05AM CDT
The Law Offices of Marc S. Henzel announces that a class action lawsuit was filed against Galena Biopharma, Inc. (Nasdaq: GALE) ("GALE" or the "Company") and certain of its officers in United States District Court for the District of Oregon on behalf of a class (the "Class") comprising all purchasers of Galena Biopharma, Inc. (Nasdaq: GALE) securities between November 6, 2013 and February 14, 2014, inclusive (the "Class Period").
Wolf Haldenstein Announces Investigation of Galena Biopharma, Inc.
Business Wire - Tue Mar 11, 5:07PM CDT
The law firm of Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating potential federal securities claims against Galena Biopharma, Inc. ("Galena" or the "Company") (NASDAQ:GALE) and certain of its officers and directors in connection with allegations that the Company made materially misleading representations and omissions in connection with a brand awareness campaign aimed at boosting its stock price.
Investor-Edge.com Pre-market Biotech Picks: Rexahn Pharma, Amgen, Galena Biopharma, and MannKind
PR Newswire - Tue Mar 11, 10:32AM CDT
On Monday, March 10, 2014, the NASDAQ Composite ended at 4,334.45, down 0.04%, the Dow Jones Industrial Average fell 0.21% to 16,418.68, and the S&P 500 closed at 1,877.17, down 0.05%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 689.78, up 0.39%, and has gained 4.92% in the last one month. Investor-Edge.com has initiated coverage on the following equities: Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Amgen Inc. (NASDAQ: AMGN), Galena Biopharma Inc. (NASDAQ: GALE), and MannKind Corporation (NASDAQ: MNKD). Free research on these four companies can be accessed at:
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Files Class Action Lawsuit Against Galena Biopharma, Inc.
Business Wire - Tue Mar 11, 9:32AM CDT
Glancy Binkow & Goldberg LLP, representing investors of Galena Biopharma, Inc. ("Galena" or the "Company") (NASDAQ:GALE), has filed a class action lawsuit in the United States District Court for the District of Oregon on behalf of a class (the "Class") comprising all purchasers of Galena securities between November 6, 2013 and February 14, 2014, inclusive (the "Class Period").
Lawsuit on Behalf of Investors in Galena Biopharma Inc (GALE) Announced by Shareholders Foundation
GlobeNewswire - Mon Mar 10, 9:02AM CDT
The Shareholders Foundation, Inc. announces that a lawsuit was filed on behalf of certain purchasers Galena Biopharma Inc (GALE) common stock over alleged violations of Federal Securities Laws by Galena Biopharma Inc in connection with certain allegedly false and misleading statements.
Shareholder Rights Law Firm Johnson & Weaver, LLP Has Filed a Class Action Lawsuit Against Galena Biopharma, Inc. and Certain Officers
Business Wire - Sat Mar 08, 5:01AM CST
Shareholder rights law firm Johnson & Weaver, LLP announced today that it filed a class action lawsuit in the United States District Court for the District of Oregon on behalf of purchasers of Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena") (GALE) common stock during the period between November 6, 2013 and February 14, 2014 (the "Class Period").
EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Against Galena Biopharma, Inc. -- GALE
GlobeNewswire - Fri Mar 07, 10:35PM CST
The Rosen Law Firm, P.A. today announced that a class action lawsuit has been filed on behalf of all purchasers of the common stock of Galena Biopharma, Inc. (Nasdaq:GALE) from November 6, 2013 to February 14, 2014, seeking remedies under the federal securities laws.
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Galena Biopharma, Inc. -- GALE
GlobeNewswire - Fri Mar 07, 6:00PM CST
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the District of Oregon on behalf of all persons who purchased or otherwise acquired the securities of Galena Biopharma, Inc. ("Galena" or the "Company") (Nasdaq:GALE) during the period between November 6, 2013 and February 14, 2014 (the "Class Period").
GALENA BIOPHARMA, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against GALENA BIOPHARMA, INC. and Its Board and a Lead Plaintiff Deadline of May 5, 2014 -- GALE
GlobeNewswire - Fri Mar 07, 2:59AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of holders of Galena Biopharma, Inc. ("Galena" or the "Company") (Nasdaq:GALE) securities between November 6, 2013 and February 14, 2014.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Galena Biopharma, Inc. to Contact Brower Piven Before the May 5, 2014 Lead Plaintiff Deadline -- GALE
GlobeNewswire - Fri Mar 07, 2:59AM CST
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of purchasers of Galena Biopharma, Inc. ("Galena" or the "Company") (Nasdaq:GALE) common stock during the period between November 6, 2013 and February 14, 2014, inclusive (the "Class Period").
Cohen, Placitella & Roth, PC Investigating Galena Biopharma, Inc. for Improper Stock Promotion
PR Newswire - Thu Mar 06, 6:20PM CST
Cohen, Placitella & Roth, PC is investigating claims on behalf of investors who purchased Galena Biopharma, Inc. ("Galena" or "Company") (NASDAQ: GALE) stock between November 6, 2013 and February 14, 2014, inclusive. The investigation concerns whether Galena disseminated materially false and/or misleading information to investors in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Galena Biopharma, Inc.
PR Newswire - Thu Mar 06, 2:02PM CST
Bernstein Liebhard LLP today announced that a class action has been commenced in the United States District Court for the District of Oregon on behalf of purchasers (the "Class") of common stock of Galena Biopharma, Inc. ("Galena" or the "Company") (NASDAQ: GALE) during the period of November 6, 2013 and February 14, 2014 (the "Class Period").
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Galena Biopharma, Inc.
Business Wire - Wed Mar 05, 6:49PM CST
Robbins Geller Rudman & Dowd LLP ("Robbins Geller") (http://www.rgrdlaw.com/cases/galena/) today announced that a class action has been commenced in the United States District Court for the District of Oregon on behalf of purchasers of Galena Biopharma, Inc. ("Galena") (NASDAQ:GALE) common stock during the period between November 6, 2013 and February 14, 2014 (the "Class Period").
Galena Biopharma to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 6:11AM CST
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer will present a corporate update at the 26 Annual ROTH Conference. The presentation will take place on Monday, March 10, 2014 at 9:00 a.m. PT at The Ritz-Carlton Hotel in Dana Point, CA.
Targazyme, Inc. Appoints Dr. Mark W. Schwartz to Board of Directors
Marketwire - Tue Mar 04, 5:01AM CST
Targazyme, Inc. (formerly America Stem Cell, Inc., the "Company") announced today that it has appointed Mark W. Schwartz, Ph.D. to the Company's Board of Directors. Dr. Schwartz will serve the Company as an independent member of the Board. As an independent director, Dr. Schwartz will assist in the Company in further enhancing its corporate governance protocols and oversight committees, as well as assist management in setting and meeting corporate goals, including establishing key strategic partnerships and providing guidance on long-term capital raising in both private and public markets. With the appointment of Dr. Schwartz as the Company's fourth Board member and third independent director, the Company has achieved Sarbanes-Oxley ("SOX") compliance with respect to Board composition.
Galena Biopharma Launches Galena Patient Services (GPS)
GlobeNewswire - Mon Mar 03, 6:05AM CST
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the launch of Galena Patient Services (GPS), a full-service support program designed to enhance patient access to commercial products offered by the Company. Currently, Galena markets Abstral(R) (fentanyl) Sublingual Tablets for the treatment of breakthrough cancer pain.
Galena Biopharma Bolsters NeuVax(TM) (nelipepimut-S) Intellectual Property With Patent Acceptance in Australia
GlobeNewswire - Fri Feb 28, 6:19AM CST
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that it has received a Notice of Acceptance from the Australian Patent Office for a patent covering the use of Galena's development product candidate, NeuVax(TM) (nelipepimut-S), a HER2/neu peptide vaccine, for inducing protective or therapeutic immunity to breast cancer recurrence in patients having low-to-intermediate HER2 IHC ratings of 1+ or 2+ and a FISH rating of less than 2.0 ± 20% for CYP17 to HER2/neu gene expression ratio. The patent provides NeuVax the exclusivity for this indication until 2028, not including any patent term extensions.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of GALENA BIOPHARMA, INC. for Possible Breaches of Fiduciary Duty
PR Newswire - Thu Feb 27, 10:10AM CST
Levi & Korsinsky is investigating Galena Biopharma, Inc. ("Galena Biopharma" or the "Company") (Nasdaq: GALE) for possible breaches of fiduciary duty. The investigation concerns whether a series of statements Galena Biopharma made regarding its business, prospects, and operations were materially false and misleading.
